Cannabidiol Oral Solution
Sponsors
INSYS Therapeutics Inc, MultiCare Health System Research Institute, Radius Pharmaceuticals, Inc., University of California, San Diego, Mariana Cherner, PhD
Conditions
Cannabis Use DisorderChildhood Absence EpilepsyDravet SyndromeEarly PsychosisEpilepsyInfantile SpasmLennox-Gastaut SyndromePrader-Willi Syndrome
Phase 1
Phase 2
Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms
TerminatedNCT02551731
Start: 2016-01-27End: 2016-09-06Updated: 2018-09-19
Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
TerminatedNCT03336242
Start: 2017-12-29End: 2019-05-29Updated: 2023-07-21
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
TerminatedNCT03355300
Start: 2018-02-20End: 2019-06-28Updated: 2023-06-18
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome
TerminatedNCT03458416
Start: 2018-09-06End: 2019-07-31Updated: 2023-06-22
CBD for Sleep in People With HIV
WithdrawnNCT05097651
Start: 2021-04-01End: 2023-08-31Updated: 2024-05-10
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
CompletedNCT05600114
Start: 2022-10-27End: 2023-12-13Updated: 2024-11-21
Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy
NCT05803434
Start: 2023-06-01End: 2025-03-01Target: 30Updated: 2023-04-18
Phase 3
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
WithdrawnNCT02318537
Start: 2017-12-30End: 2018-06-30Updated: 2018-01-04
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
WithdrawnNCT02318563
Start: 2017-12-30End: 2018-06-17Updated: 2018-01-04
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
CompletedNCT02318602
Start: 2016-01-08End: 2017-06-22Updated: 2018-07-26
A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms
TerminatedNCT03421496
Start: 2018-09-05End: 2019-05-29Updated: 2023-06-07
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
RecruitingNCT04411225
Start: 2022-06-01End: 2026-12-31Target: 120Updated: 2026-01-08